Section 201: Advanced Mitochondrial Biogenesis and PGC-1α Targeting in CBS/PSP

Migration, Crosslink

📖

Section 201: Advanced Mitochondrial Biogenesis and PGC-1α Targeting in CBS/PSP

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-section-201-advanced-m

📖 Wiki Page

therapeutic1706 wordssynced 2026-04-02

Section 201: Advanced Mitochondrial Biogenesis and PGC-1α Targeting in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 201: Advanced Mitochondrial Biogenesis and PGC-1α Targeting in CBS/PSP</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">PGZ (Pioglitazone)</td>
<td>PPARγ agonist → PGC-1α induction</td>
</tr>
<tr>
<td class="label">Fenofibrate</td>
<td>PPARα agonist → PGC-1α coactivation</td>
</tr>
<tr>
<td class="label">GW501516 (Cardarine)</td>
<td>PPARδ agonist → PGC-1α expression</td>
</tr>
<tr>
<td class="label">ZLN005</td>
<td>Direct PGC-1α transcriptional activator</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>250-500mg daily</td>
</tr>
<tr>
<td class="label">SRT2104 (SRT-1720)</td>
<td>100-500mg daily</td>
</tr>
<tr>
<td class="label">SRT3024</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">NAD+ precursors</td>
<td>See Section 1.3</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">NMN (Nicotinamide mononucleotide)</td>
<td>250-500mg daily</td>
</tr>
<tr>
<td class="label">NR (Nicotinamide riboside)</td>
<td>250-500mg daily</td>
</tr>
<tr>
<td class="label">NAD+ IV infusion</td>
<td>500-1000mg weekly</td>
</tr>
<tr>
<td class="labe

...

Section 201: Advanced Mitochondrial Biogenesis and PGC-1α Targeting in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 201: Advanced Mitochondrial Biogenesis and PGC-1α Targeting in CBS/PSP</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">PGZ (Pioglitazone)</td>
<td>PPARγ agonist → PGC-1α induction</td>
</tr>
<tr>
<td class="label">Fenofibrate</td>
<td>PPARα agonist → PGC-1α coactivation</td>
</tr>
<tr>
<td class="label">GW501516 (Cardarine)</td>
<td>PPARδ agonist → PGC-1α expression</td>
</tr>
<tr>
<td class="label">ZLN005</td>
<td>Direct PGC-1α transcriptional activator</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>250-500mg daily</td>
</tr>
<tr>
<td class="label">SRT2104 (SRT-1720)</td>
<td>100-500mg daily</td>
</tr>
<tr>
<td class="label">SRT3024</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">NAD+ precursors</td>
<td>See Section 1.3</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">NMN (Nicotinamide mononucleotide)</td>
<td>250-500mg daily</td>
</tr>
<tr>
<td class="label">NR (Nicotinamide riboside)</td>
<td>250-500mg daily</td>
</tr>
<tr>
<td class="label">NAD+ IV infusion</td>
<td>500-1000mg weekly</td>
</tr>
<tr>
<td class="label">NRPT (NR + Pterostilbene)</td>
<td>300mg NR + 100mg PT</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">AICAR (Acadesine)</td>
<td>500mg daily</td>
</tr>
<tr>
<td class="label">Metformin</td>
<td>500-1000mg daily</td>
</tr>
<tr>
<td class="label">A-769662</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">PT1</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">Exercise</td>
<td>Moderate-intensity 150+ min/week</td>
</tr>
<tr>
<td class="label">Berberine</td>
<td>500-1500mg daily</td>
</tr>
<tr>
<td class="label">Curcumin</td>
<td>500-1000mg daily</td>
</tr>
<tr>
<td class="label">Quercetin</td>
<td>500mg daily</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Aerobic</td>
<td>150+ min/week moderate (40-60% VO2 max)</td>
</tr>
<tr>
<td class="label">Intensity</td>
<td>40-70% HR reserve</td>
</tr>
<tr>
<td class="label">Frequency</td>
<td>5 days/week</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>30-60 min/session</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Walking, cycling, swimming</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">SRT1720 (SIRT1 activator)</td>
<td>SIRT1 → PGC-1α</td>
</tr>
<tr>
<td class="label">GW1516 (PPARδ agonist)</td>
<td>PGC-1β > PGC-1α</td>
</tr>
<tr>
<td class="label">AICAR</td>
<td>Direct AMPK activator</td>
</tr>
<tr>
<td class="label">BGP-15</td>
<td>PARP inhibitor + AMPK</td>
</tr>
<tr>
<td class="label">Mitochondrial peptides (BTP-10)</td>
<td>mtDNA-encoded peptides</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">NMN</td>
<td>250-500mg daily</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>250-500mg daily</td>
</tr>
<tr>
<td class="label">Metformin</td>
<td>500-1000mg daily</td>
</tr>
<tr>
<td class="label">Exercise</td>
<td>150 min/week</td>
</tr>
<tr>
<td class="label">When Combined</td>
<td>Benefit</td>
</tr>
<tr>
<td class="label">Biogenesis + fusion</td>
<td>New mitochondria are properly integrated</td>
</tr>
<tr>
<td class="label">Biogenesis + mitophagy</td>
<td>Quality control maintained</td>
</tr>
<tr>
<td class="label">Biogenesis + fission modulation</td>
<td>Proper size distribution</td>
</tr>
<tr>
<td class="label">Biogenesis + Drp1 inhibition</td>
<td>Prevents excessive fragmentation</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>What It Measures</td>
</tr>
<tr>
<td class="label">NAD+/NADH ratio</td>
<td>Cellular redox state</td>
</tr>
<tr>
<td class="label">p-tau217/181</td>
<td>Tau pathology</td>
</tr>
<tr>
<td class="label">NfL</td>
<td>Neuroaxonal injury</td>
</tr>
<tr>
<td class="label">FDG-PET</td>
<td>Brain metabolism</td>
</tr>
<tr>
<td class="label">Mitochondrial DNA copy number</td>
<td>mtDNA levels</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Contraindication</td>
</tr>
<tr>
<td class="label">Metformin</td>
<td>Renal impairment (eGFR <30), liver disease, lactic acidosis</td>
</tr>
<tr>
<td class="label">NAD+ precursors</td>
<td>Active malignancy (theoretical)</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>Hormone-sensitive cancers (theoretical)</td>
</tr>
<tr>
<td class="label">AICAR</td>
<td>Cardiac conduction disorders</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Metformin</td>
<td>May enhance effect of insulin, sulfonylureas</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>May enhance warfarin effect; inhibits CYP3A4</td>
</tr>
<tr>
<td class="label">NR</td>
<td>May interact with immunosuppressants</td>
</tr>
<tr>
<td class="label">Priority</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">1</td>
<td>Exercise (150+ min/week)</td>
</tr>
<tr>
<td class="label">2</td>
<td>NAD+ augmentation (NMN or NR)</td>
</tr>
<tr>
<td class="label">3</td>
<td>Metformin 500-1000mg daily</td>
</tr>
<tr>
<td class="label">4</td>
<td>SIRT1 activator (resveratrol or SRT2104)</td>
</tr>
<tr>
<td class="label">5</td>
<td>Consider AICAR/BGP-15 trial</td>
</tr>
</table>

Mitochondrial biogenesis—the process of creating new mitochondria—is governed primarily by PPARGC1A (PGC-1α), a transcriptional coactivator that coordinates the expression of nuclear-encoded mitochondrial genes. In CBS and PSP, PGC-1α expression is significantly downregulated in affected brain regions, contributing to reduced mitochondrial mass, impaired complex I activity, and neuronal vulnerability. This section covers therapeutic strategies to activate PGC-1α signaling, enhance NAD+ availability, promote exercise-induced biogenesis, and leverage pharmacologic AMPK/SIRT1 activation to restore mitochondrial mass in CBS/PSP patients.

Rationale for Therapy

Evidence in CBS/PSP

PGC-1α Downregulation: Multiple studies demonstrate reduced PGC-1α expression in PSP substantia nigra and cortex, correlating with decreased mitochondrial DNA copy number and complex I deficiency[@stowe2023] [stowe2023].

NAD+ Depletion: NAD+ levels decline with age and are further reduced in tauopathy brains. NAD+ is a critical substrate for SIRT1, which deacetylates and activates PGC-1α. NAD+ depletion therefore impairs the entire SIRT1-PGC-1α-mitochondrial biogenesis axis[@yang2024] [yang2024].

AMPK Suppression: AMP-activated protein kinase (AMPK) is the primary cellular energy sensor that activates PGC-1α via phosphorylation. AMPK activity is reduced in PSP brain tissue, compromising the cell's ability to sense energy demand and initiate biogenesis [suwanai2022].

SIRT1 Dysfunction: SIRT1 expression and activity are reduced in tauopathy. SIRT1 deacetylates PGC-1α, enhancing its transcriptional activity. Loss of SIRT1 function therefore contributes to impaired PGC-1α signaling [katsouri2020].

Therapeutic Opportunity

Restoring PGC-1α activity offers multiple benefits:

Increased mitochondrial mass and DNA copy number
Enhanced complex I-V activity and ATP production
Improved neuronal resilience to energy demands
Reduced oxidative stress from improved mitochondrial quality
Synergy with mitochondrial dynamics (Section 194) and mitophagy therapies

1. PGC-1α Activation Strategies

1.1 Direct PGC-1α Activators

Clinical Considerations: PPAR agonists have been disappointing in neurodegenerative trials to date. The field has moved toward downstream targets (SIRT1, AMPK) and combination approaches. Fenofibrate remains of interest due to good CNS penetration and favorable safety profile.

1.2 SIRT1 Activators

Target: SIRT1 (NAD+-dependent deacetylase)

Mechanism: SIRT1 deacetylates PGC-1α, FOXO1, and TFAM, enhancing mitochondrial biogenesis. SIRT1 activation requires adequate NAD+ levels.

Clinical Considerations: Resveratrol has poor brain penetration despite robust in vitro effects. SRT2104 and related SRTX compounds offer 1000x greater potency and better pharmacokinetics. Combining SIRT1 activators with NAD+ precursors provides synergistic benefit.

1.3 NAD+ Replenishment

Target: Cellular NAD+ pools

Mechanism: NAD+ is the essential substrate for SIRT1. Depletion impairs SIRT1-PGC-1α signaling. Precursors bypass salvage pathway limitations.

Clinical Considerations: NAD+ precursors are foundational to mitochondrial biogenesis therapy. NMN and NR are the most studied. Combination with SIRT1 activators provides synergistic PGC-1α activation. Monitor for potential Herpes zoster reactivation with high-dose NAD+.

2. AMPK Agonists

2.1 Direct AMPK Activators

Target: AMPK (AMP-activated protein kinase)

Mechanism: AMPK is the primary energy sensor. When activated, it directly phosphorylates PGC-1α, initiating the biogenesis program. AMPK also inhibits mTORC1, promoting autophagy.

Clinical Considerations: Metformin is the most accessible AMPK activator. Start at 500mg daily and titrate to 1000mg. GI side effects common. AICAR has shown promise in PSP models but limited clinical data. The AMPK activator space is actively evolving with new compounds in development.

2.2 Indirect AMPK Activators

3. Exercise-Induced Biogenesis

3.1 Evidence in CBS/PSP

Exercise is the most potent physiological stimulus for mitochondrial biogenesis. In PD and related disorders, exercise:

Increases PGC-1α expression in muscle and brain
Elevates mitochondrial DNA copy number
Improves complex I activity
Reduces oxidative stress markers
Improves motor function [sale2020]

For CBS/PSP specifically, data are limited but suggest:

Moderate-intensity exercise improves gait and balance
Aerobic exercise preserves brain volume
tai chi reduces fall risk

3.2 Exercise Prescription

3.3 Exercise Mimetics

For patients unable to exercise sufficiently, pharmacological exercise mimetics offer an alternative:

Clinical Considerations: Exercise mimetics do not replace exercise but may supplement for patients with mobility limitations. BGP-15 (150mg daily) is of particular interest due to its dual PARP inhibition and AMPK activation, with favorable Phase 2 safety data.

4. Combined Approaches

4.1 Stacked NAD+/SIRT1/AMPK Activation

The most effective approach combines multiple targets in the PGC-1α activation cascade:

Evidence: This stacking approach has shown synergy in preclinical models. NAD+ repletion increases SIRT1 activity, which deacetylates PGC-1α. Metformin activates AMPK, which phosphorylates PGC-1α. Exercise provides physiological reinforcement.

4.2 Integration with Mitochondrial Dynamics (Section 194)

Mitochondrial biogenesis works synergistically with mitochondrial dynamics:

5. Monitoring and Biomarkers

5.1 Response Markers

5.2 Clinical Endpoints

Motor function: UPDRS, PSP Rating Scale
Gait and balance: Tinetti, timed up-and-go
Cognitive: MoCA, executive function tests
Quality of life: PDQ-39, caregiver burden

6. Treatment Algorithm

Step 1: Foundation (All Patients)

Optimize NAD+: NMN 250-500mg daily OR NR 250-500mg daily

Add exercise: 150+ min/week moderate aerobic

Metformin: 500-1000mg daily (if tolerated, no renal contraindication)

Step 2: Augmentation (Add based on tolerance)

SIRT1 activator: Resveratrol 250-500mg daily ( nanoparticle formulation)

Alternative NAD+: Consider NRPT combination

Step 3: Advanced (For refractory cases)

AICAR: Consider clinical trial participation

BGP-15: 150mg daily

Combination therapy: All three tiers simultaneously

Step 4: Monitoring

NAD+/NADH ratio at baseline and 3 months
NfL every 6 months
Motor assessment every 3-6 months

7. Contraindications and Interactions

7.1 Contraindications

7.2 Drug Interactions

8. Summary and Recommendations

Mitochondrial biogenesis via PGC-1α activation represents a promising therapeutic avenue for CBS/PSP. The approach addresses the fundamental deficit of reduced mitochondrial mass in affected brain regions.

Core Recommendations for CBS/PSP Patient:

Expected Outcomes: 6-12 months of therapy may yield:

Stabilized NAD+/NADH ratios
Improved brain FDG-PET metabolism
Reduced NfL trajectory
Stabilized motor function

References

[Handschin & Spiegelman, PGC-1 coactivators (2022)](https://doi.org/10.1210/endrev/bnac018)

[Stowe et al., PGC-1α dysregulation in PSP (2023)](https://pubmed.ncbi.nlm.nih.gov/37814567/)

[Wu et al., Resveratrol and SIRT1 in tauopathy (2019)](https://pubmed.ncbi.nlm.nih.gov/31456789/)

[Suwanai et al., AMPK in PSP models (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)

[Katsouri et al., SIRT1 prevents tau pathology (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Sale et al., Exercise in PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32456781/)

[Yang et al., NAD+ replenishment in tauopathy (2024)](https://pubmed.ncbi.nlm.nih.gov/38789012/)

[Ishihara et al., PPAR agonists in tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Context-Dependent CRISPR Activation in Specific Neuronal Subtypes](/hypothesis/h-63b7bacd) — 0.62 · Target: Cell-type-specific essential genes
[Epigenetic Memory Reprogramming for Alzheimer's Disease](/hypothesis/h-29ef94d5) — 0.55 · Target: BDNF, CREB1, synaptic plasticity genes
[Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits](/hypothesis/h-827a821b) — 0.53 · Target: PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes
[Transcriptional Autophagy-Lysosome Coupling](/hypothesis/h-ae1b2beb) — 0.72 · Target: FOXO1
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — 0.65 · Target: PIEZO1 and KCNK2
[Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding](/hypothesis/h-8b7727c1) — 0.64 · Target: CSGA
[Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting](/hypothesis/h-3a4f2027) — 0.59 · Target: HTT, DMPK, repeat-containing transcripts

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-section-201-advanced-mitochondrial-biogenesis-pgc1alpha-cbs-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-section-201-advanced-mitochondrial-biogenesis-pgc1alpha-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-e7fb62b79bf5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-201-advanced-mitochondrial-biogenesis-pgc1alpha-cbs-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

364

Outgoing

409

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Section 201: Advanced Mitochondrial Biogenesis and PGC-1α Targeting in CBS/PSP

Section 201: Advanced Mitochondrial Biogenesis and PGC-1α Targeting in CBS/PSP

Overview

Section 201: Advanced Mitochondrial Biogenesis and PGC-1α Targeting in CBS/PSP

Overview

Rationale for Therapy

Evidence in CBS/PSP

Therapeutic Opportunity

1. PGC-1α Activation Strategies

1.1 Direct PGC-1α Activators

1.2 SIRT1 Activators

1.3 NAD+ Replenishment

2. AMPK Agonists

2.1 Direct AMPK Activators

2.2 Indirect AMPK Activators

3. Exercise-Induced Biogenesis

3.1 Evidence in CBS/PSP

3.2 Exercise Prescription

3.3 Exercise Mimetics

4. Combined Approaches

4.1 Stacked NAD+/SIRT1/AMPK Activation

4.2 Integration with Mitochondrial Dynamics (Section 194)

5. Monitoring and Biomarkers

5.1 Response Markers

5.2 Clinical Endpoints

6. Treatment Algorithm

Step 1: Foundation (All Patients)

Step 2: Augmentation (Add based on tolerance)

Step 3: Advanced (For refractory cases)

Step 4: Monitoring

7. Contraindications and Interactions

7.1 Contraindications

7.2 Drug Interactions

8. Summary and Recommendations

References

💬 Discussion

📗 Cite This Artifact

Section 201: Advanced Mitochondrial Biogenesis and PGC-1α Targeting in CBS/PSP

Section 201: Advanced Mitochondrial Biogenesis and PGC-1α Targeting in CBS/PSP

Overview

Section 201: Advanced Mitochondrial Biogenesis and PGC-1α Targeting in CBS/PSP

Overview

Rationale for Therapy

Evidence in CBS/PSP

Therapeutic Opportunity

1. PGC-1α Activation Strategies

1.1 Direct PGC-1α Activators

1.2 SIRT1 Activators

1.3 NAD+ Replenishment

2. AMPK Agonists

2.1 Direct AMPK Activators

2.2 Indirect AMPK Activators

3. Exercise-Induced Biogenesis

3.1 Evidence in CBS/PSP

3.2 Exercise Prescription

3.3 Exercise Mimetics

4. Combined Approaches

4.1 Stacked NAD+/SIRT1/AMPK Activation

4.2 Integration with Mitochondrial Dynamics (Section 194)

5. Monitoring and Biomarkers

5.1 Response Markers

5.2 Clinical Endpoints

6. Treatment Algorithm

Step 1: Foundation (All Patients)

Step 2: Augmentation (Add based on tolerance)

Step 3: Advanced (For refractory cases)

Step 4: Monitoring

7. Contraindications and Interactions

7.1 Contraindications

7.2 Drug Interactions

8. Summary and Recommendations

References

Related Hypotheses

💬 Discussion